Roche has won CE Mark certification under the European Union's In Vitro Diagnostic Regulation (IVDR) for the cobas smart e immunoanalyser — a compact, standalone benchtop platform built to bring central-laboratory-grade immunoassay testing into smaller hospitals and local labs that have historically had to send such tests out. The Basel-based diagnostics group announced the mark on 27 October 2026, alongside a planned menu of more than 100 assays across cardiometabolic, oncology and infectious-disease testing, all built on the same Elecsys chemistry and reagent packs that run Roche's larger cobas e immunoassay systems.
cobas smart e, by the record
Figures from Roche's 27 October 2026 announcement and product materials.
A $47 billion test market, mostly still centralized
cobas smart e is entering a large category and a tiny one at the same time. The global immunoassay testing market — every chemiluminescence, ELISA and related assay run on every analyser, in every lab, for every disease area — was estimated at $35.5 billion in 2025 and is forecast to reach $47.7 billion by 2030, a 6.1% compound annual growth rate, according to MarketsandMarkets. Almost all of that volume still runs on large, shared, high-throughput systems in centralized or reference laboratories. The specific category cobas smart e was engineered for — compact, benchtop, automated immunoassay analysers built for smaller or decentralized sites — is a far smaller slice: Intel Market Research put the benchtop automated immunoassay analyzer segment at about $650 million in 2025, rising toward $1.2 billion by 2034, a separate report from ReportPrime landing on a similar roughly $640 million 2025 base. The gap between those two numbers is the opportunity Roche is describing: a large, well-established testing category where most volume still has to travel to get tested, and a small but growing segment of hardware built to keep more of it local.
Immunoassay testing's climb to $47.7 billion
$35.5B → $47.7B
Global immunoassay testing, 2025 to 2030, as forecast by MarketsandMarkets (December 2025); the benchtop/decentralized analyser segment cobas smart e specifically enters is far smaller, estimated near $650 million in 2025 by Intel Market Research.
Sources: MarketsandMarkets, “Global Immunoassay Market to Hit USD 47.7 Billion by 2030,” via GlobeNewswire, 8 December 2025. · Intel Market Research, Bench-Top Automated Immunoassay Analyzer Market Report, 2025.
Regulatory News outlook
We expect decentralized, benchtop immunoassay placements — the segment cobas smart e is built for — to grow faster than the segment's own published forecast implies, toward roughly $875 million by 2030, as cost-pressured hospitals and local labs in-source testing they currently send out to reference laboratories.
How we got here: Intel Market Research's $650 million 2025 base for benchtop automated immunoassay analyzers, compounded at the broader immunoassay market's 6.1% CAGR (MarketsandMarkets, 2025–2030) rather than the narrower segment's own slower published growth rate.
cobas smart e next to three other benchtop lines
| Product | Form factor | Menu | Throughput | Typical setting |
|---|---|---|---|---|
| cobas smart e (Roche) | Standalone benchtop, <1 m² footprint, 36 reagent positions | 100+ assays planned (cardiometabolic, oncology, infectious disease) | 90%+ of assays in ≤18 min; up to 2 hrs walkaway on 36 samples | Smaller hospitals, local/decentralized labs |
| LIAISON XL (DiaSorin) | Benchtop, compact footprint | ~105 assays (company figures) | Up to 180 tests/hour | Small-to-medium labs |
| Atellica IM 1300 (Siemens Healthineers) | Floorstanding, modular; shares footprint with IM 1600 | Core immunoassay menu (company labelling) | Up to 220 tests/hour | Mid-to-high-volume labs |
| VIDAS 3 (bioMérieux) | Benchtop, single-test ELFA cartridges | 80+ assays (company figures) | Up to 36 tests/hour | Small labs, critical care, point-of-care-adjacent |
From each company's labelling and announcements; not a clinical comparison.
One countertop, the same chemistry as a reference lab
Roche's pitch for cobas smart e is continuity, not reinvention. The analyser runs the same system reagents and Elecsys electrochemiluminescence chemistry as the cobas e 402 and cobas e 801 modules that stock Roche's larger, high-throughput laboratories — the company's stated reasoning is that a result from the countertop system should match a result from the central lab, rather than requiring its own separate validation and reference ranges. Roche says more than 90% of its immunoassays react in 18 minutes or less on the platform, and that the full standalone system, including sample and reagent handling, occupies a footprint of under one square metre with 36 onboard reagent positions and up to two hours of walkaway time on a full load of 36 samples.
The rest of the pitch is about what a smaller site does not have to build around the box. Roche describes an integrated water tank, compatibility with standard power supplies, and dust-protection engineering intended to reduce the specialised plumbing, power and environmental infrastructure that larger immunoassay platforms typically require. The company also claims roughly one minute of daily operator intervention and up to a two-thirds reduction in hands-on maintenance compared with prior-generation platforms — figures that come from Roche's own release and trade coverage of it, not from an independent evaluation, and that this reporting could not verify against a published study.
Three things cobas smart e is betting on
Same chemistry, smaller room
Elecsys reagents and system chemistry shared with the cobas e 402 and e 801 modules, so a result from the countertop system is meant to be comparable to one from Roche's largest central-lab platforms, not a separate validated method.
Infrastructure the site doesn't have to add
An integrated water tank, standard power compatibility and dust-protection engineering, aimed at sites without the plumbing, power and environmental build-out larger immunoassay systems typically need.
A referral-sized menu, not a panel
A planned menu of more than 100 assays across cardiometabolic, oncology and infectious-disease testing — positioned against the narrower menus of many compact or point-of-care-adjacent immunoassay systems.
What a CE Mark under IVDR actually certifies
The EU's In Vitro Diagnostic Regulation, Regulation (EU) 2017/746, replaced the older IVD Directive with a risk-based classification system and, for most device classes, a requirement that an independent Notified Body assess conformity before a CE Mark can be applied. A CE Mark under IVDR is a determination that a device meets the regulation's safety, performance and quality-management requirements — it is not a reimbursement decision, and it does not by itself set a commercial launch date in any particular EU member state. Roche's 27 October release does not name the Notified Body that carried out the conformity assessment, give the device's Basic UDI-DI, or state a country-by-country commercial rollout sequence; the public EUDAMED device registry had not indexed a public entry for cobas smart e as of this writing.
“For smaller hospitals and laboratories, maintaining central-lab quality has traditionally meant outsourcing tests.” Matt Sause, CEO, Roche Diagnostics — 27 October 2026 announcement
A 130-year-old chemistry company's newest countertop machine
The path to a countertop analyser
- 1896
Roche founded
Fritz Hoffmann-La Roche founds the company in Basel, Switzerland, which remains Roche's global headquarters.
- 20 June 2016
cobas e 801 launched
Roche launches the cobas e 801 immunoassay module for high-throughput central laboratories — part of the cobas e platform whose Elecsys chemistry cobas smart e now shares.
- 27 October 2026
CE Mark for cobas smart e
Roche announces CE Mark certification under the EU's IVDR for the cobas smart e immunoanalyser, positioned for smaller hospitals and local labs.
- Ahead
Rollout and menu build-out
Roche's announcement gives no commercial availability date, country sequence or list price, and describes the 100-plus-assay menu as still being built out rather than complete at CE Mark.
- Regulatory status: CE Mark under the EU's IVDR, announced 27 October 2026; no U.S. FDA submission or clearance for cobas smart e was identified in the record.
- Menu: more than 100 assays planned across cardiometabolic, oncology and infectious-disease testing; the release does not confirm every assay is available at CE Mark.
- Footprint and workflow: under one square metre, 36 reagent positions, up to two hours of walkaway time on a full sample load, and roughly one minute of daily operator attention, by Roche's own description.
- Still open: commercial availability dates, country-by-country sequencing, list pricing, the Notified Body involved and the complete assay roster were not disclosed in the 27 October release.
What the announcement does not say is almost as notable as what it does. For regulatory and market-access readers, cobas smart e is, for now, a CE Mark and a set of company-stated specifications — not yet a priced, dated, country-sequenced product launch. We will update this page as Roche's EUDAMED entry, pricing and country rollout become public.
Sources & further reading
- Roche, “Roche obtains new CE mark in its cobas range for the compact cobas smart e immunoanalyser,” media release, roche.com, 27 October 2026. roche.com
- RTTNews, “Roche Received CE Mark For New Compact Immunoassay Analyzer,” 27 October 2026. rttnews.com
- Indian Pharma Post, “Roche Wins CE Mark For Compact Immunoanalyser Targeting Diagnostic Delays In Smaller Labs,” 27 October 2026. indianpharmapost.com
- Chemxplore, “Roche cobas smart e immunoanalyser gains CE Mark,” 27 October 2026. chemxplore.com
- Option Finance, “Roche obtient un nouveau marquage CE pour sa gamme cobas,” 27 October 2026. optionfinance.fr
- Roche, “Roche launches the new cobas e 801 module, helping hospitals meet the demand for increased diagnostic testing,” media release, roche.com, 20 June 2016. roche.com
- Roche, cobas smart e product overview, diagnostics.roche.com. diagnostics.roche.com
- Roche, Investor Relations — ticker and listing information (SIX: RO, ROP; OTCQX: RHHBY). roche.com
- MarketsandMarkets, “Global Immunoassay Market to Hit USD 47.7 Billion by 2030, Driven by Rising Chronic and Infectious Diseases,” via GlobeNewswire, 8 December 2025. globenewswire.com
- Intel Market Research, Bench-Top Automated Immunoassay Analyzer Market Report, 2025. intelmarketresearch.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did Roche receive CE Mark for?
The cobas smart e immunoanalyser, a compact, standalone benchtop immunoassay platform, received CE Mark certification under the EU's In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746). Roche announced the mark on 27 October 2026 from Basel.
What is the cobas smart e built for?
A benchtop system, under one square metre, built to run Roche's existing Elecsys chemistry and reagent packs on a single countertop. Roche positions it for smaller hospitals and local or decentralized laboratories that have traditionally sent immunoassay testing out to reference labs, rather than for large central-lab networks.
How large is the assay menu, and is it available today?
Roche says it plans a menu of more than 100 assays spanning cardiometabolic, oncology and infectious-disease testing. CE Mark permits Roche to place the device on the market across the EU/EEA; the 27 October release does not give a country-by-country rollout date, a list price, or confirm that all 100-plus assays are available at launch.
Is cobas smart e Roche's first benchtop immunoassay analyser?
No. It joins an existing cobas e immunoassay line that includes the higher-throughput cobas e 402 and cobas e 801 modules. Roche's point is that cobas smart e runs the same underlying Elecsys chemistry and reagents as those larger systems, in a far smaller footprint, rather than introducing a new, separate chemistry.
Has cobas smart e been cleared by the U.S. FDA?
Roche's CE Mark announcement is an EU/EEA authorization under IVDR. It does not mention a U.S. FDA submission or clearance for cobas smart e, and no separate FDA record for the device was identified in this reporting.
